Oculis plans a late-2026 filing to study privosegtor as a potential neuroprotective treatment for acute MS relapse.

A new mathematical model that reproduces the relapsing-remitting pattern of multiple sclerosis (MS) offers scientists a tool to better understand how ...

Prenatal and early life sun exposure was associated with lower risk for relapse in children with pediatric-onset multiple sclerosis (MS), a new prospective cohort study showed. At least 30 minutes of ...

The FDA Division of Neurology provided positive feedback supporting a regulatory pathway for Privosegtor in acute multiple sclerosis (MS) relapses, addressing a significant unmet medical need  The FDA ...

A blood test might predict when multiple sclerosis patients are about to suffer a relapse in their symptoms, a new study says. Blood levels of a protein called neurofilament light chain rise ...

Modern therapies have transformed care for people with multiple sclerosis (MS). Yet the disease continues to progress in a substantial proportion of patients, even in the absence of relapses.

Over one-third of MS patients do not fully recover post-relapse, with severity as the strongest predictor of incomplete recovery. Relapse-associated worsening (RAW) is crucial in understanding ...

October 12, 2012 (Lyon, France) — Final results of a phase 3 trial comparing 2 doses of teriflunomide (Aubagio, Genzyme/Sanofi), 14 mg/d and 7 mg/d, vs placebo in patients with relapsing multiple ...

People with multiple sclerosis (MS) have an increased risk of severe coronavirus infection, but there has been concern regarding potential relapse after vaccination. A new study finds that people with ...

Clinical data from the HERCULES trial show that tolebrutinib reduces six-month confirmed disability progression by 31% in non ...

"Medical Journeys" is a set of clinical resources reviewed by doctors, meant for physicians and other healthcare professionals as well as the patients they serve. Each episode of this journey through ...